Description

An antibody is a protein component of the immune system that circulates in the blood, recognizes foreign substances like bacteria and viruses, and neutralizes them. After exposure to a foreign substance, called an antigen, antibodies continue to circulate in the blood, providing protection against future exposures to that antigen. According to a report by StrategyHelix, the global antibody drugs market is set to increase by US$ 72.34 billion during 2021-2027, growing at a CAGR of 9.4% during the forecast period.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for antibody drugs. The global antibody drugs market is segmented on the basis of product, process, diseases, and region. On the basis of product, the globalantibody drugs market has been segmented into chimeric mAbs, human mAbs, humanized mAbs, and others. Human mAbs was the largest revenue contributor to the global antibody drugs market in 2020 and is anticipated to show the highest growth rate during the forecast period. By process, the globalantibody drugs market has been segmented into mammalian cell culture, and microbial fermentation. Based on diseases, the globalantibody drugs market is categorized into autoimmune diseases, multiple myeloma, lymphoma, and leukemia, solid tumors, and others. Geographically, the globalantibody drugs market is segmented into Asia Pacific, Europe, and North America.

The global antibody drugs market is highly competitive. Key companies profiled in the report include AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the antibody drugs market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: chimeric mAbs, human mAbs, humanized mAbs, and others
Process: mammalian cell culture, and microbial fermentation
Diseases: autoimmune diseases, multiple myeloma, lymphoma, and leukemia, solid tumors, and others
Region: Asia Pacific, Europe, and North America
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

– Get a comprehensive picture of the global antibody drugs market
– Pinpoint growth sectors and trends for investment

Table of Contents

1. Market definition
2. Research methodology
3. Market data and outlook
3.1 Market size estimates
3.2 Forecast
4. Antibody drugs market by product
4.1 Chimeric mAbs
4.2 Human mAbs
4.3 Humanized mAbs
4.4 Others
5. Antibody drugs market by process
5.1 Mammalian cell culture
5.2 Microbial fermentation
6. Antibody drugs market by diseases
6.1 Autoimmune diseases
6.2 Multiple myeloma, lymphoma, and leukemia
6.3 Solid tumors
6.4 Others
7. Antibody drugs market by region
7.1 Asia Pacific
7.2 Europe
7.3 North America
8. Company profiles
8.1 AbbVie Inc.
8.2 Amgen Inc.
8.3 AstraZeneca plc
8.4 Biogen Inc.
8.5 Bristol-Myers Squibb Company
8.6 Eli Lilly and Company
8.7 F. Hoffmann-La Roche AG
8.8 GlaxoSmithKline plc
8.9 Johnson & Johnson
8.10 Merck & Co. Inc.
8.11 Novartis AG
8.12 Pfizer Inc.
8.13 Sanofi S.A.
9. Appendix
9.1 About StrategyHelix
9.2 Disclaimer